ArticleThe Journal of nutrition2008
Rosmarinic acid antagonizes activator protein-1-dependent activation of cyclooxygenase-2 expression in human cancer and nonmalignant cell lines.
Article in The Journal of nutrition, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 129 citations in OpenAlex.
- Aesthetic Radiofrequency Associated withJournal of evidence-based integrative medicineTrial
- "Purple Rain, Purple Rain": RSM Optimization and Bioactivity Assessment of Rosmarinic Acid-RichPlants (Basel, Switzerland) · 2026Article
- From Plant Propagation to Anticancer Activity: Phytochemical and Biological Evaluation of Water Extracts ofMolecules (Basel, Switzerland) · 2026Article
- Mechanistic insights into polyphenolic constituents from traditional Chinese medicines in inhibiting colorectal cancer metastasis.Natural products and bioprospecting · 2026Review
- Wound Healing Potential of the Salvianolic Acid H and Yunnaneic Acid B-The Rosmarinic Acid Derivatives: Anti-Inflammatory Action and Hemocompatibility In Vitro.Molecules (Basel, Switzerland) · 2026Article
- Review
- Rosmarinic Acid: A Potential Therapeutic Agent in Gastrointestinal Cancer Management-A Review.International journal of molecular sciences · 2024Review
- The role of the miR-30a-5p/BCL2L11 pathway in rosmarinic acid-induced apoptosis in MDA-MB-231-derived breast cancer stem-like cells.Frontiers in pharmacology · 2024Article
- Rosmarinic acid, the active component of Rubi Fructus, induces apoptosis of SGC-7901 and HepG2 cells through mitochondrial pathway and exerts anti-tumor effect.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Modulation of MAPK/NF-κB Pathway and NLRP3 Inflammasome by Secondary Metabolites from Red Algae: A Mechanistic Study.ACS omega · 2023Article
- Comprehensive Insights into Biological Roles of Rosmarinic Acid: Implications in Diabetes, Cancer and Neurodegenerative Diseases.Nutrients · 2023Review
- Exploring the anti-cancer potential of dietary phytochemicals for the patients with breast cancer: A comprehensive review.Cancer medicine · 2023Review
- An Update on the Therapeutic Anticancer Potential ofMolecules (Basel, Switzerland) · 2023Review
- Detoxification of comfrey (Frontiers in pharmacology · 2023Article
- Article
- Journey of Rosmarinic Acid as Biomedicine to Nano-Biomedicine for Treating Cancer: Current Strategies and Future Perspectives.Pharmaceutics · 2022Review
- Rosmarinic Acid and Related Dietary Supplements: Potential Applications in the Prevention and Treatment of Cancer.Biomolecules · 2022Review
- Anticancer Effect of Spices Used in Mediterranean Diet: Preventive and Therapeutic Potentials.Frontiers in nutrition · 2022Review
- Hydroxycinnamic Acids and Derivatives Formulations for Skin Damages and Disorders: A Review.Pharmaceutics · 2021Review
- Synergistic Herb-Herb Interaction of the Antinociceptive and Anti-Inflammatory Effects ofEvidence-based complementary and alternative medicine : eCAM · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
One mechanism through which bioactive food components may exert anticancer effects is by reducing the expression of the proinflammatory gene cyclooxygenase-2 (COX-2), which has been regarded as a risk factor in tumor development. Rosmarinic acid (RA) is a phenolic derivative of caffeic acid present in rosemary (Rosmarinus officinalis). Previous research documented that RA may exert antiinflammatory effects. However, the mechanisms of action of RA on COX-2 expression have not been investigated. Here, we report that in colon cancer HT-29 cells, RA (5, 10, and 20 micromol/L) reduced the 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced COX-2 promoter activity (P < 0.05) and protein levels (P < 0.05). In addition, the cotreatment with RA reduced (5 micromol/L, P < 0.05; 10 and 20 micromol/L, P < 0.01) TPA-induced transcription from a control activator protein-1 (AP-1) promoter-luciferase construct and repressed binding of the AP-1 factors c-Jun (10 micromol/L; P < 0.01) and c-Fos (10 micromol/L; P < 0.05) to COX-2 promoter oligonucleotides harboring a cAMP-response element (CRE). The anti-AP1 effects of RA were also examined in a nonmalignant breast epithelial cell line (MCF10A) in which RA antagonized the stimulatory effects of TPA on COX-2 protein expression (5 micromol/L, P < 0.05; 10 and 20 micromol/L, P < 0.01), the recruitment of c-Jun and c-Fos (10 micromol/L; P < 0.01) to the COX-2/CRE oligonucleotides, and activation of the extracellular signal-regulated protein kinase-1/2 (ERK1/2) (10 micromol/L; P < 0.01), a member of the mitogen-activated protein kinase pathway. Additionally, RA antagonized ERK1/2 activation in colon HT-29 and breast MCF-7 cancer cells (10 micromol/L; P < 0.01). Thus, we propose that RA may be an effective preventative agent against COX-2 activation by AP-1-inducing agents in both cancer and nonmalignant mammary epithelial cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.